香港股市 已收市

Idorsia Ltd (0RQE.IL)

IOB - IOB 延遲價格。貨幣為 CHF。
加入追蹤清單
2.8290+0.2670 (+10.42%)
收市:05:56PM GMT
全螢幕
前收市價2.5620
開市2.6880
買盤2.7020 x 無
賣出價2.9700 x 無
今日波幅2.5720 - 2.9680
52 週波幅1.2940 - 10.1749
成交量44,085
平均成交量122,330
市值717.862M
Beta 值 (5 年,每月)0.66
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-4.5700
業績公佈日
遠期股息及收益率無 (無)
除息日
1 年預測目標價
  • Reuters

    Viatris forecasts strong 2024 sales on higher demand for branded drugs

    Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday, banking on strong demand for its branded drugs such as Yupelri for lung disease and Breyna for asthma. Viatris was formed with the merger of Mylan and Pfizer's Upjohn business and has generic and key branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication Xanax, epilepsy treatment Lyrica and arthritis treatment Celebrex. CEO Scott Smith said Viatris would focus on growing its base business, which consists of its generic and branded drugs portfolio, this year, including through research partnerships such as its deal with Switzerland-based biotech Idorsia that was announced earlier on Wednesday.